Replies to post #66310 on Biotech Values

[ghmm]

Infergen:

I am just glad Dan Welch sold it to Valeant for what in hindsight was great timing. I believe it held some potential in treatment failures particularly daily dosing (before Protease Inhibitors showed promise). I believe InterMune was to get a milestone upon completion of that (daily dosing) trial but I haven't kept up with what happened.